The company was selected into the "2022 China Small Molecule Drug Enterprise Innovation Power TOP30 Ranking"

The company was awarded "Enterprise with the Most Investment Value of the Year" at the 3rd Jiangsu Capital Market Summit

Co-built the China AIDS Prevention and Control Innovative Drug Research Demonstration Base

Aitribond® (Ainuomiti/ACC008 Tablets) was included in the National Medical Insurance Catalog, and Ainuovirine/ACC007 Tablets successfully renewed its contract